Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
575.00    -2.00 (-0.35%)
Bid:
577.00
Ask:
581.00
Spread: 4.00 (0.693%)
Market Cap: £500.97m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

21 Jul 2015 07:00

RNS Number : 5569T
Victrex PLC
21 July 2015
 



 

 

 

 

 

 

21 July 2015

 

Victrex plc - Interim Management Statement

 

"Solid trading and acquisition of Kleiss Gears"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its Interim Management Statement for the period 1 April 2015 to 30 June 2015 (Q3) and the acquisition of Kleiss Gears Incorporated for a cash consideration of approximately $6m.

 

Victrex saw solid trading against tougher comparatives during Q3, with our performance reflecting continuing growth across our industrial markets, which is offsetting sales to Oil & Gas and a lower contribution from our Invibio medical business. Third quarter Group revenue of £64.5m was flat compared to the prior year period (Q3 2014: £64.2m) and slightly ahead in constant currency, with third quarter Group sales volume of 1,070 tonnes 17% ahead of the prior year (Q3 2014: 911 tonnes). Year to date Group sales volume of 3,098 tonnes is 24% ahead of the prior year (YTD 2014: 2,495 tonnes).

 

Within Victrex Polymer Solutions (VPS), Consumer Electronics volumes remain strong and, as previously communicated, we expect volumes from the current opportunity to continue through our 2016 financial year.

 

In our Invibio medical business, the sales improvement trend we saw in Q2 did not continue as we anticipated during Q3. Overall sales were down during the quarter, driven lower by the continued effects of consolidation in the US medical device industry. However, outside of the US, sales in Europe and emerging markets remain positive. On a full year basis, we now anticipate Invibio revenue will be lower than 2014. Our expectation is for full year sales to decline by a broadly similar level to the 4% reduction seen in the first half year.

 

All of our new product platforms and adoption programmes continue to make positive progress, including those in medical for PEEK-OPTIMA® HA-Enhanced (Spine), Dental, Trauma and Knee.

 

Acquisition of Kleiss Gears

Victrex is pleased to announce the acquisition of Kleiss Gears, a US based polymer gears' manufacturer, for approximately $6m (£3.8m) in cash.

 

Kleiss has over 20 years' experience of unique design and precision moulding capability in gears, and will benefit from Victrex's materials know-how, existing customer relationships and global commercial reach. Kleiss has early stage commercialisation of PEEK gear programmes, alongside the rest of its mainly industrial focused gears business.

 

The acquisition is in line with Victrex's strategy of moving further downstream and investing in growth acceleration opportunities for its pipeline projects. It offers the opportunity to accelerate Victrex's PEEK gear proposition to the automotive industry, in line with our aim to double the amount of PEEK volume in cars over the medium term.

 

For its 2014 financial year, Kleiss had revenues of approximately $4m and employed 26 people.

 

Outlook

For the year as a whole, whilst challenges continue in the Oil & Gas market and in improving Invibio's performance, our overall momentum remains positive and we still expect to fully overcome the impact of foreign currency. Consequently, and reflecting our balanced portfolio, Victrex remains well positioned to deliver profit progress over the full year.

 

Cash generation remains healthy and there have been no significant changes to the Group's financial position since our interim results announcement.

 

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Tuesday 21 July at 08.00am UK time. For dial in details please contact Laura Stewart at Pendomer Communications: laura.stewart@pendomer.com or +44 (0) 203 603 5229.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEASXEAEDSEFF
Date   Source Headline
9th Jul 20217:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202110:23 amRNSTotal Voting Rights
17th Jun 202111:29 amRNSDirector/PDMR Shareholding
16th Jun 20212:13 pmRNSAdditional Listing
2nd Jun 202111:10 amRNSDirector/PDMR Shareholding
1st Jun 20219:35 amRNSBlock listing Interim Review
28th May 20211:09 pmRNSTotal Voting Rights
18th May 20214:50 pmRNSDirector Declaration
18th May 202110:32 amRNSDirector/PDMR Shareholding
17th May 202110:56 amRNSDirector/PDMR Shareholding
13th May 202110:08 amRNSAdditional Listing
10th May 20217:00 amRNSVictrex plc Interim Results
30th Apr 20212:41 pmRNSTotal Voting Rights
19th Apr 20212:37 pmRNSDirector/PDMR Shareholding
16th Apr 202110:36 amRNSDirector Declaration
9th Apr 202111:00 amRNSAdditional Listing
31st Mar 20211:52 pmRNSTotal Voting Rights
17th Mar 20211:41 pmRNSDirector/PDMR Shareholding
1st Mar 202111:37 amRNSDirector/PDMR Shareholding
26th Feb 20211:47 pmRNSTotal Voting Rights
17th Feb 202110:32 amRNSDirector/PDMR Shareholding
12th Feb 20211:53 pmRNSResult of AGM
12th Feb 20217:00 amRNSAGM and Q1 Interim Management Statement
10th Feb 20212:37 pmRNSDirector/PDMR Shareholding
29th Jan 20212:33 pmRNSTotal Voting Rights
19th Jan 20213:50 pmRNSDirector/PDMR Shareholding
7th Jan 20212:06 pmRNSAnnual Report and Accounts
6th Jan 20212:34 pmRNSDirector/PDMR Shareholding
31st Dec 20209:00 amRNSTotal Voting Rights
17th Dec 20203:09 pmRNSDirector/PDMR Shareholding
15th Dec 202012:57 pmRNSDirector/PDMR Shareholding
11th Dec 20202:47 pmRNSDirector/PDMR Shareholding
9th Dec 20207:00 amRNSVictrex plc – Preliminary Results 2020
1st Dec 202010:59 amRNSBlock listing Interim Review
30th Nov 202011:24 amRNSTotal Voting Rights
17th Nov 20209:49 amRNSDirector/PDMR Shareholding
30th Oct 202011:40 amRNSTotal Voting Rights
19th Oct 202011:34 amRNSDirector/PDMR Shareholding
14th Oct 202012:17 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSVictrex plc Full Year Trading Statement
30th Sep 20209:30 amRNSTotal Voting Rights
29th Sep 20204:09 pmRNSHolding(s) in Company
17th Sep 202011:00 amRNSDirector/PDMR Shareholding
28th Aug 20209:56 amRNSTotal Voting Rights
19th Aug 202011:01 amRNSDirector/PDMR Shareholding
31st Jul 202011:53 amRNSTotal Voting Rights
20th Jul 202010:45 amRNSDirector/PDMR Shareholding
17th Jul 20204:43 pmRNSDirector/PDMR Shareholding
8th Jul 20207:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202011:30 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.